BioXcel Therapeutics
BTAI
31 hedge funds and large institutions have $770K invested in BioXcel Therapeutics in 2025 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 12 reducing their positions, and 24 closing their positions.
325% more call options, than puts
Call options by funds: $17K | Put options by funds: $4K
10.43% more ownership
Funds ownership: 1.09% → 11.52% (+10%)
17% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 12
37% less funds holding
Funds holding: 49 → 31 (-18)
75% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 24
76% less capital invested
Capital invested by funds: $3.22M → $770K (-$2.46M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
M
Murchinson
Toronto,
Ontario, Canada
|
+$508K |
| 2 |
Goldman Sachs
New York
|
+$92.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$82K |
| 4 |
BPA
Beacon Pointe Advisors
Newport Beach,
California
|
+$70.4K |
| 5 |
VF
Virtu Financial
New York
|
+$35.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.61M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$207K |
| 3 |
Millennium Management
New York
|
-$39.2K |
| 4 |
Renaissance Technologies
New York
|
-$29.1K |
| 5 |
State Street
Boston,
Massachusetts
|
-$28.8K |
BTAI Hedge Fund Activity: Q1 2025 in Review
31 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q1 2025, worth a combined $770K — down 76% from $3.22M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of BTAI and 6 opened new positions — a net loss of 18 holders — while 12 trimmed existing stakes and 10 added.
The largest buyer was Murchinson, opening a new position worth an estimated $508K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.61M sold.
- 31 institutional investors held BioXcel Therapeutics (BTAI) as of Q1 2025, down from 49 in Q4 2024.
- Funds reported $770K of BioXcel Therapeutics stock for Q1 2025, down 76% quarter-over-quarter.
- 6 funds opened new BioXcel Therapeutics positions in Q1 2025 and 24 closed out, a net change of -18 holders.
- The largest BioXcel Therapeutics buyer in Q1 2025 was Murchinson, an estimated $508K added.
- The largest BioXcel Therapeutics seller in Q1 2025 was Armistice Capital, an estimated $1.61M sold.
Based on aggregated 13F filings for Q1 2025.